Pharma BD Deal Intelligence

Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business)

2016 · Asset Purchase · $1.0B · Complete

WRONG BY 41 POINTS

Mylan's $1B dermatology bet took two confirmed impairment hits within two years, and the assets disappeared into segment-level reporting before being absorbed into Viatris with no standalone accounting ever surfacing again.

Full analysis, sources & comparables →

The coverage arc

May 13, 2016 FiercePharma Bullish

Mylan snapped up the Renaissance dermatology business for ~$1B, with FiercePharma noting the deal complements the pending Meda dermatology assets and signals a…

May 16, 2016 Pharmaceutical Technology Neutral

Pharmaceutical Technology framed the transaction as Mylan adding ~25 marketed topicals plus a ~25-product pipeline and a topicals CDMO, characterizing it as a…

Jun 15, 2016 Mylan / PR Newswire - Mylan Completes Acquisition of Renaissance Topicals Bullish

CEO Heather Bresch: 'By bringing together the Renaissance topicals business with Mylan's existing assets and the pending addition of Meda... we will become a…

Source summaries from our enrichment pipeline; follow links for originals.

All 9 sources with sentiment breakdown →

Mylan acquired the non-sterile topicals-focused specialty and generics business of Renaissance Acquisition Holdings for $950M cash at closing plus contingent payments up to $50M (~$1B total). Acquired ~25 branded/generic topical products, an active pipeline of ~25 products, U.S. dermatology sales infrastructure, and integrated manufacturing. Closed June 15, 2016. ~$370M in 2015 revenues.

Did it work? Outcome assessment

Mylan's $1B dermatology bet took two confirmed impairment hits within two years, and the assets disappeared into segment-level reporting before being absorbed into Viatris with no standalone accounting ever surfacing again.

Strategic verdict
Failed to Achieve
Financial impact
Neutral
Pipeline outcome
Mixed

Key facts

Related deals — scored

DealYearValueOutcome
Mylan N.V. / Renaissance Acquisition Holdings, LLC (topicals business) (this deal)2016$1.0B40
Mylan N.V. / Meda AB2016$9.9B53
Mylan N.V. / Upjohn Inc. (Pfizer)2019$12.0B44
Mylan N.V. / Novartis AG (TOBI franchise)2018$463M38
Mylan N.V. / Perrigo Company plc2015$26.0B
Ciba-Geigy AG / Sandoz AG1996$36.3B98
Sanofi SA / Regeneron Pharmaceuticals, Inc.2007$1.0B97

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →